

PERSONAL INFORMATION

Christian Gisselbrecht

WORK EXPERIENCE

September 1981–September
2010**professor hematology, head hematology oncology department**

hôpital Saint Louis Paris VII university (France)

treatment lymphoma

stem cell transplantation

clinical research: phase 1, 2,3 studies

chair : multicentric and international studies

September 1975–September
1981**chief resident hematology**

hôpital saint louis Paris VII university (France)

treatments of hematologic malignancies

pharmacology of antineoplastic agents

November 1987–October 2003

president

non profit association GELA (France)

organization of clinical studies among 100 centers France and Belgium for all type of lymphoma.

Phase 2, 3

EDUCATION AND TRAINING

November 1969–October 1975

MD. 1975 resident hematology oncology

hôpital saint louis paris VII university (France)

medical training in hematology

treatment of lymphoma, leukemia

stem cell transplantation

CAR T

September 1971–July 1972

certificate of molecular biology

Paris VII university of sciences (France)

training in molecular biology

September 1972–February 1974

visiting research associate

national institute of health (NIH) Bethesda (United States)

mechanisms of enzymes activation by the liver

drugs metabolism

September 1981–October 2010

full professor hematology

Paris VII university Diderot (France)

University teaching for graduate or post-graduate, medical students in Hematology, Seminars - Oncology - Hematology for post-Doctorat students, Director of thesis.

Research focus on clinical studies in hematology

October 2010–Present

professor emeritus hematology

hôpital saint louis paris VII university (France)
 evaluation of antineoplastic agents, new drugs
 evaluation of clinical studies
 evaluation of treatment of lymphoma and other hematologic malignancies
 autologous stem cell transplantation
 regulatory aspects of clinical studies

ADDITIONAL INFORMATION

Expertise

Main Topics of Interest :

- stem cell transplantation.: clinical results, conditioning regimens, toxicity
- CAR T cell
- Non Hodgkin's and Hodgkin lymphoma.
- Pharmacology of antineoplastic agents: drug resistance.
- Monoclonal antibodies in lymphoma
- Clinical studies in lymphoma: prognostication, chemotherapy, CAR T
- biology and pathology of lymphoma.
- Pharmacotherapeutics

Publications

PUBLICATIONS from 2009 – 2018 (300 in medline)

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?

Gisselbrecht C.

J Clin Oncol. 2018 Sep 17;JCO1800498. doi: 10.1200/JCO.18.00498. [Epub ahead of print] No abstract available.

New perspectives in the therapeutic approach of peripheral T-cell lymphoma.

Gisselbrecht C, Sibon D.

Curr Opin Oncol. 2018 Sep;30(5):285-291. doi: 10.1097/CCO.0000000000000469.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Jun 12. pii: S2352-3026(18)30051-6. doi: 10.1016/S2352-3026(18)30051-6. [Epub ahead of print] Review.

How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Gisselbrecht C, Van Den Neste E.

Br J Haematol. 2018 Sep;182(5):633-643. doi: 10.1111/bjh.15412. Epub 2018 May 29. Review.

Tzogani K, Camarero Jiménez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. *Oncologist*. 2017 Sep 21. pii: theoncologist.2017-0184. doi: 10.1634/theoncologist.2017-0184.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2017 Aug 7. pii: S1083-8791(17)30623-7. doi:

10.1016/j.bbmt.2017.07.027

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. *Clin Lymphoma Myeloma Leuk*. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. *Cancer*. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. 2016 Sep 19.

Gisselbrecht C. Is nivolumab an option for Hodgkin's lymphoma? *Lancet Oncol*. 2016 Sep;17(9):1183-4.

Broséus J, Chen G, Hergalant S, Ramstein G, Mounier N, Guéant JL, Feugier P, Gisselbrecht C, Thieblemont C, Houlgatte R. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. *Oncotarget*. 2016 Jun 2.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. *Leuk Lymphoma*. 2016 Dec;57(12):2820-2826.

Nieto M, Demolis P, Béhanzin E, Moreau A, Hudson I, Flores B, Stemplewski H, Salmonson T, Gisselbrecht C, Bowen D, Pignatti F. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jun;21(6):692-700.

Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. *Ann Oncol*. 2016 Mar;27(3):390-7.

Gravanis I, Tzoganis K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jan;21(1):102-9. 26621039

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Briere J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. 2016 Jan;51(1):51-7.

de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, Lamant L, Delarue R, Berger F, Arbion F, Bossard C, Copin MC, Canioni D, Charlotte F, Damaj G, Dartigues P, Fabiani B, Ledoux-Pilon A, Montagne K, Molina T, Patey M, Tas P, Pech M, Petit B, Petrella T, Picquenot JM, Rousset T, Rousselet MC, Soubeyran I, Thiebault S, Tournilhac O, Xerri L, Gisselbrecht C, Haioun C, Delsol G, Gaulard P. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct

French information data sets. *Haematologica*. 2015 Sep;100(9):e361-4.

Hess G, Coiffier B, Crump M, Gisselbrecht C, Offner F, Romaguera J, Kang L, Moran Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. *PJ. Exp Hematol Oncol*. 2015 Apr 11;4:11.

Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2015;56(10):2863-9.

Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F.

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2015 Mar;20(3):329-34

Mounier N, Gisselbrecht C.

Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. *Expert Rev Hematol*. 2015 Apr;8(2):205-16.

Gisselbrecht C.

Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma?

J Clin Oncol. 2014; 32(31):3472-3.

Gisselbrecht C.

Futility of relapsed diffuse large B cell lymphoma transplantation?

Biol Blood Marrow Transplant. 2014; 20(11):1667-9.

E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste

Biol Blood Marrow Transplant. 2014; 20(12):1905-11.

Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B.

A randomized study of interferon α -2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.

Oncologist. 2013; 18(11):1189.

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozák T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol*. 2013 May 1;31(13):1624-30.

Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24.

Gisselbrecht C.: Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? *Hematology Am Soc Hematol Educ Program*. 2012;2012:410-6. doi: 10.1182/asheducation-2012.1.410. Review

Gisselbrecht C. TP53 mutations and rituximab-CHOP. *Blood*. 2012 Nov 8;120(19):3867-9.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B. Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. *J Clin Oncol*. 2012 Dec 20;30(36):4462-9

Mounier N, Gisselbrecht C. Relapses, treatments and new drugs. *Best Pract Res Clin Haematol*. 2012 Mar;25(1):49-60.

Gisselbrecht C. Preface. *Best Pract Res Clin Haematol*. 2012 Mar;25(1):1-2.

- Ribrag V, Caballero D, Ferme C, Zucca E, Arranz R, Briones J, Gisselbrecht C, Salles G, Gianni AM, Gomez H, Kahatt C, Corrado C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Cavalli F. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. *Haematologica*. 2013 Mar;98(3):357-63
- Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H. Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Etude des Lymphomes de l'Adulte Trials. *J Clin Oncol*. 2012 Nov 10;30(32):3939-46.
- Valleron W, Ysebaert L, Berquet L, Fataccioli V, Quelen C, Martin A, Parrens M, Lamant L, de Leval L, Gisselbrecht C, Gaulard P, Brousset P. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. *Blood*. 2012 Nov 8;120(19):3997-4005
- De Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. *Ann Oncol*. 2012 Dec;23(12):3143-51.
- Gisselbrecht C. Current approaches to the treatment of non-Hodgkin's lymphoma. *Hematol Rep*. 2011 Oct 28;3(3s):e3.
- Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirschaud E, Ysebaert L, Bron D, Soulier J, Gaulard P, Houlgatte R, Gisselbrecht C, Thieblemont C. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. *Blood*. 2012 May 17;119(20):4619-24.
- Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT). High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. *Biol Blood Marrow Transplant*. 2012 May;18(5):788-93.
- Martis N, Gisselbrecht C, Mounier N. Quality of life following treatment for B-cell lymphoma. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Oct;11(5):523-32. Review.
- Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirschaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. *J Clin Oncol*. 2011 Nov 1;29(31):4079-87.
- Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. *Clin Lymphoma Myeloma Leuk*. 2011 Apr;11(2):212-8.
- Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. *Haematologica*. 2011 Aug;96(8):1136-43.
- Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte. Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. *Leuk Lymphoma*. 2011 Jul;52(7):1239-48.
- Gisselbrecht C. A revival: radioimmunotherapy in mucosa associated lymphoid tissue lymphoma. *Leuk Lymphoma*. 2011 Feb;52(2):159-60.
- O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol*. 2011 Mar 20;29(9):1182-9.
- Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. *Curr Opin Oncol*. 2011 Mar;23(2):209-13. Review.
- Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody-based approaches to non-Hodgkin lymphoma. *Leuk Lymphoma*. 2010 Aug;51 Suppl 1:20-7. Review.
- Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier

- N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA). Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. *Leuk Lymphoma*. 2010 Sep;51(9):1668-77.
- Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, Mounier N, Gisselbrecht C, Faure P, Thieblemont C. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. *Clin Lymphoma Myeloma Leuk*. 2010 Aug;10(4):262-9.
- Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. 2010 Sep 20;28(27):4184-90.
- Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. *Blood*. 2010 Aug 19;116(7):1092-104.
- Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. *J Clin Oncol*. 2010 Apr 20;28(12):2085-93.
- Gisselbrecht C. Molecular signatures in T-cell lymphoma. *Blood*. 2010 Feb 4;115(5):919-20.
- Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prirituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. *J Clin Oncol*. 2010 Feb 10;28(5):822-9.
- De Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. *Br J Haematol*. 2010 Mar;148(5):673-89.
- Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. *Summary. Oncologist*. 2009;14 Suppl 2:52-4. Review.
- Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. *Oncologist*. 2009;14 Suppl 2:41-51. Review.
- Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. *Oncologist*. 2009;14 Suppl 2:30-40.
- Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. *Oncologist*. 2009;14 Suppl 2:4-16.
- Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. *Introduction. Oncologist*. 2009;14 Suppl 2:1-3.
- Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. *J Clin Oncol*. 2009 Nov 20;27(33):5573-9.
- Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. *Semin Oncol*. 2009 Aug;36(4 Suppl 2):S25-34. Review.
- Thieblemont C, Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. *Curr Oncol Rep*. 2009 Sep;11(5):386-93. Review.
- Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). *Cancer*. 2009 Oct 1;115(19):4540-6.
- Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III study to evaluate

temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol*. 2009 Aug 10;27(23):3822-9.

Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morschhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. *Ann Oncol*. 2009 Dec;20(12):1985-92.

Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie-Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. *Ann Oncol*. 2009 Mar;20(3):503-7.

Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. *Br J Haematol*. 2009 Feb;144(3):367-75.

Projects focus on diffuse large B cell lymphoma: DLBCL
Outcome of relapsed DLBCL and treatment CAR T
Chair of the international study on relapsed DLBCL :CORAL
Chairman of several phase II , phase III studies from 1987 to 2003
Advisor for several studies on other types of lymphoma.
Participation in several IDMC
Co-founder of cooperative group on Lymphoma : GELA in 1987, now LYSA

Memberships memberships: American Society of Clinical Oncology, American Society of Cancer Research, Société Française d'Hématologie, International Society of Hematology, American Society of Hematology, European Blood Marrow Transplantation, European Hematology Association.
Lymphoma study association/GELA: founding member president 1987 to 2002
editorial board:., *Clinical Lymphoma and myeloma*, *Haematologica*, *Brazilian Journal of Hematology and Hemotherapy*.
Faculty 1000
Expert for :Drug Agency (AFSSAPS, ANSM), EMA 2010-2018 SAG oncology
Numerous invitations in international conferences: ASCO, ASH, EHA, EBMT. society of hematology: turkish, Japanese, chinese, corean, danish, brazil, spanish, french, german, british, italian, Irish, belgium, swiss, sweden

Other Relevant Information Expert ONIAM